Novobiocin attacks BRCA-mutated cancer cells from within and without, study shows

As the first clinical trial of the drug novobiocin is about to open for patients with cancers carrying BRCA gene mutations, new research at Dana-Farber Cancer Institute shows the drug poses a double threat to tumor cells.

Leave A Comment

Your email address will not be published. Required fields are marked *